Top Tweets for #SABCSUpdate
Join us tonight for #SABCSUpdate #1!
💬 Datopotamab Deruxtecan for HR+/HER2– Breast Cancer: Results From the Phase 3 TROPION-Breast01 Trial
👥 @dradityabardia, @marijasullivan, & @MeganTesch
🕓 4:00 PM EST
📆 https://t.co/Ea9efwifGy
2. #KN522: SOC neo/adjuvant Pembro + Chemo for high-risk TNBC
⬆️ EFS: HR 0.63
⬆️ OS: HR 0.72 (immature)
- No new safety signals
- Real-world analyses Vs study data on KN522 ⤵️
#SABCSUpdate #breastcancer
1. #SABCS22 updates w/@maryam_lustberg from @YaleCancer @YaleBreast on #TNBC:
- A deeper dive, real-world analysis, and updates on #KN522
https://t.co/qhUp4JRnNn
#bcsm #SABCSUpdate
@OncoAlert @SoMeCME @SABCSSanAntonio
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on neo/adjuvant IO in early triple-negative #breastcancer w/ @maryam_lustberg & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/4pHafKqRoR
📊 What is your specialty❓
2. T-DXd for HER2+ BC:
▶️ T-DXd: Improved 2L outcomes vs T-DM1 in Ph3 DB03 (full approval)
▶️ T-DXd: Improved 3L/4L outcomes vs physician’s choice after T-DM1 in Ph3 DB02
Besides breast cancer, TDXd is also approved in Her 2+ GI malignancies & mERBB2 lung Ca
#SABCSUpdate
1. #SABCS22 updates w/ @ErikaHamilton9 from @SarahCannonDocs on Her 2 #breastcancer:
- #APT and #ATEMPT: de-escalating studies update
- #DestinyBreast 02, 03, and 04: TDxD in mBC updates
https://t.co/4fKGDZcbOw
#bcsm #SABCSUpdate
@OncoAlert @SoMeCME @SABCSSanAntonio
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates in HER2+ metastatic #breastcancer w/ @erikahamilton9 & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/SBLP7ItIt3
📊 What is your specialty❓
2/ 🗣️ How will OS outcomes from DB03 & DB02 affect treatment sequencing in your practice?
T-DXd for HER2+ BC:
▶️ T-DXd: Improved 2L outcomes vs T-DM1 in Ph3 DB03 (full approval)
▶️ T-DXd: Improved 3L/4L outcomes vs physician’s choice after T-DM1 in Ph3 DB02
#SABCSUpdate
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates in HER2+ metastatic #breastcancer w/ @erikahamilton9 & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/SBLP7ItIt3
📊 What is your specialty❓
⭐ Join @OncBrothers, @ErikaHamilton9, & @SoMeCME for #SABCS22 conference coverage designed for community oncologists! Get the latest data on HER2+ & HER2-low breast cancer, beginning at 6:00 PM EST.
Be sure to leave comments & share your thoughts using #SABCSUpdate!
📣 Upcoming live activities on @SoMeCME!
⭐ #SABCSUpdate #3: https://t.co/keQVXpAXvw
🩺 #SABCSUpdate #4: https://t.co/X2yn8Z3Rxa
Earn 🆓 #CME here: https://t.co/AXxKRwsPfM
2. #Sacituzumab govitecan (Trop-2/TOP1 ADC) is already approved for TNBC and bladder cancer.
#TROPiCS2 Ph3, HR+/HER2- aBC after ET/CDK4/6i, & ≥2 L chemo:
- Met PFS (HR 0.66) & OS (0.79) endpoint
- Pending approval
- Benefit across all TROP-2 expressions
#SABCSUpdate
1. #SABCS22 updates w/ @DrSGraff from @BrownUCancer on HR+ #breastcancer:
- #TAM01 "BabyTam"
- #EMERALD: Elacestrant
- #CAPItello291: Capivasertib
- #TROPiCS2: Sacituzumab Govitecan
https://t.co/c3OFI7jb6N
#bcsm #SABCSUpdate
@OncoAlert @SoMeCME @SABCSSanAntonio
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- advanced #breastcancer w/ @DrSGraff & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/AxyPrqAEIi
📊 What is your specialty❓
2/ 🗣️ How often do you use sacituzumab govitecan for heavily pretreated patients?
▶️ Saci (Trop-2/TOP1 ADC) recommended, but not FDA indicated, for HR+/HER2- aBC after ET, CDK4/6i, & ≥2 lines of chemo
▶️ TROPiCS-02 (Ph3, saci vs chemo): met PFS & OS endpoints
#SABCSUpdate
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- advanced #breastcancer w/ @DrSGraff & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/AxyPrqAEIi
📊 What is your specialty❓
📱 Set a reminder for our next #SABCSUpdate launch at 6:00 PM EST on @SoMeCME
⭐ Join @OncBrothers & @DrSGraff for the latest data on heavily-preteated patients with HER2- advanced breast cancer, & how it applies to your practice!
1. #SABCS22 updates w/ @stolaney1 from @DFCI_BreastOnc on CDK 4/6i in HR+ #breastcancer:
- #monarchE
- #Monarch2
- #PACE
https://t.co/erO78JGNsn
#bcsm #SABCSUpdate @OncoAlert @HemOncFellows @SoMeCME
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- #breastcancer w/ @stolaney1 & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/h5mVuQDPSY
📊 What is your specialty❓
6/ We hope you enjoyed this #breastcancer education❗️
Complete the posttest & evaluation here 👉 https://t.co/TyEH2bNsEp & claim your 🆓 CME!
🗓️ Don’t miss the next #SABCSUpdate w/ @DrSGraff on Thursday, December 15th!
4/ Interim analysis of monarchE OS (adjuvant ET ± abemaciclib) presented at #SABCS22
📽️ Watch @stolaney1 & @OncBrothers discuss results & how you can implement them in clinic ⤵️
Supporting slides & transcript: https://t.co/fQOXCtL881
#SABCSUpdate
https://t.co/zXcbD2834L
2/ 🗣️ Are you using adjuvant abemaciclib in your practice? Why/why not? Share below! ⤵️
Adjuvant CDK4/6 inhibitors in HR+/HER2- EBC:
▶️ Abemaciclib (monarchE): reduced risk of IDFS & DRFS; approved
▶️ Palbociclib (PALLAS): no benefit
▶️ Ribociclib (NATALEE): ongoing
#SABCSUpdate
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- #breastcancer w/ @stolaney1 & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/h5mVuQDPSY
📊 What is your specialty❓
📱 Join @OncBrothers, @stolaney1, & @SoMeCME for exciting #SABCS22 conference coverage designed for community oncologists, beginning at 6:00 PM EST! Get the latest data on CDK4/6i & how it affects your practice!
Be sure to leave comments & share your thoughts using #SABCSUpdate!
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.9M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.5M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.3M followers
Taylor Swift
@taylorswift13
81.1M followers
Lady Gaga
@ladygaga
72.7M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.3M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.7M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62M followers
CNN
@cnn
61.9M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.4M followers